Helene Barone

Helene Barone

Auto-generated profile, based on publicly available information

Helene Barone

Regional Resource Center for Autism, ADHD, Tourette Syndrome and Narcolepsy, Western Norway, Division of Psychiatry, Haukeland University Hospital, Norway

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
SHSelina Cannon Homaei
Selina Cannon Homaei
HBHelene Barone
Helene Barone
RKRune Kleppe
Rune Kleppe
NBNibal Betari
Nibal Betari
ARAndreas Reif
Andreas Reif
JHJan Haavik
Jan Haavik
Neurometabolic diseases (NMDs) are typically caused by genetic abnormalities affecting enzyme functions, which in turn interfere with normal development and activity of the nervous system. Although the individual disorders are rare, NMDs are collectively relatively common and often lead to lifelong difficulties and high societal costs. Neuropsychiatric manifestations, including ADHD symptoms, are prominent in many NMDs, also when the primary biochemical defect originates in cells and tissues outside the nervous system. ADHD symptoms have been described in phenylketonuria, tyrosinemias, alkaptonuria, succinic semialdehyde dehydrogenase deficiency, X-linked ichthyosis, maple syrup urine disease, and several mitochondrial disorders, but are probably present in many other NMDs and may pose diagnostic and therapeutic challenges. Here we review current literature linking NMDs with ADHD symptoms. We cite emerging evidence that many NMDs converge on common neurochemical mechanisms that interfere with monoamine neurotransmitter synthesis, transport, metabolism, or receptor functions, mechanisms that are also considered central in ADHD pathophysiology and treatment. Finally, we discuss the therapeutic implications of these findings and propose a path forward to increase our understanding of these relationships.

21 October 2019 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Open access
PDF file
HBHelene Barone
Helene Barone
YBYngve T. Bliksrud
Yngve T. Bliksrud
IEIrene B. Elgen
Irene B. Elgen
PSPeter D. Szigetvari
Peter D. Szigetvari
RKRune Kleppe
Rune Kleppe
JHJan Haavik
Jan Haavik
Hereditary tyrosinemia Type 1 (HT‐1) is a rare metabolic disease where the enzyme catalyzing the final step of tyrosine breakdown is defect, leading to accumulation of toxic metabolites. Nitisinone inhibits the degradation of tyrosine and thereby the production of harmful metabolites, however, the concentration of tyrosine also increases. We investigated the relationship between plasma tyrosine concentrations and cognitive functions and how tyrosine levels affected enzyme activities of human tyrosine hydroxylase (TH) and tryptophan hydroxylase 2 (TPH2). Eight Norwegian children between 6 and 18 years with HT‐1 were assessed using questionnaires measuring Attention Deficit Hyperactivity Disorder (ADHD)‐symptoms and executive functioning. Recent and past levels of tyrosine were measured and the enzyme activities of TH and TPH2 were studied at conditions replicating normal and pathological tyrosine concentrations. We observed a significant positive correlation between mean tyrosine levels and inattention symptoms. While TH exhibited prominent substrate inhibition kinetics, TPH2 activity also decreased at elevated tyrosine levels. Inhibition of both enzymes may impair syntheses of dopamine, noradrenaline, and serotonin in brain tissue. Inattention in treated HT‐1 patients may be related to decreased production of these monoamines. Our results support recommendations of strict guidelines on plasma tyrosine levels in HT‐1. ADHD‐related deficits, particularly inattention, should be monitored in HT‐1 patients to determine whether intervention is necessary.